Company news

Edgewise Therapeutics, Inc. news in 2026

Edgewise Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

November 5, 2026

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

November 4, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

November 2, 2026

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

October 8, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

October 1, 2026

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

September 22, 2026

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

August 24, 2026

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

July 13, 2026

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

July 13, 2026

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

June 16, 2026

Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

June 1, 2026

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

June 1, 2026

Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

May 7, 2026

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

March 9, 2026

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

March 3, 2026

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

March 2, 2026

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

February 25, 2026

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

February 4, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

February 1, 2026

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

January 12, 2026

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

January 5, 2026

Decks in 2026